Portfolio company
PulseSight Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
This company develops non-viral gene therapies for patients with severe eye diseases including age-related macular degeneration.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Cirrus Therapeutics
This company develops gene and cell therapies to treat age-related macular degeneration and chronic vision loss for patients with blinding eye diseases.
Ikarovec
This company develops bicistronic gene therapies to treat chronic ophthalmic diseases, such as age-related macular degeneration, for patients suffering from vision loss.
Beacon Therapeutics
This company develops ophthalmic gene therapies to restore vision for patients with rare and prevalent retinal diseases causing blindness.
Adverum Biotechnologies
The company develops ocular gene therapies to treat retinal diseases for patients with vision-threatening conditions such as wet age-related macular degeneration.
Nightstar
This company develops gene therapies for patients with rare inherited retinal diseases that cause progressive blindness.
Ray Therapeutics
The company develops optogenetic gene therapies to restore vision for patients with blinding retinal diseases.
Gyroscope Therapeutics
This clinical-stage company develops gene therapies and surgical delivery devices for patients with vision loss caused by geographic atrophy and macular degeneration.
Perfuse Therapeutics
The company develops sustained-release intravitreal therapies to treat ischemia-driven ocular diseases for patients with conditions like glaucoma and diabetic retinopathy.